ATE302607T1 - Tartrate des 5,8,14-triazatetracyclo(10.3.1.02, 11.04,9)-hexadeca-2(11),3,5,7,9-pentaens - Google Patents

Tartrate des 5,8,14-triazatetracyclo(10.3.1.02, 11.04,9)-hexadeca-2(11),3,5,7,9-pentaens

Info

Publication number: ATE302607T1
Authority: AT; Austria
Prior art keywords: triazatetracyclo; pentaene; hexadeca; tartrate
Prior art date: 2001-05-14

Application number

AT02722625T

Other languages

English (en)

Inventor

David Everett Bogle

Peter Robert Rose

Glenn Robert Williams

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-14

Filing date

2002-04-26

Publication date

2005-09-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23117845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE302607(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-04-26 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2005-09-15 Application granted granted Critical

2005-09-15 Publication of ATE302607T1 publication Critical patent/ATE302607T1/de

Links

FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 title 1
229940095064 tartrate Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Virology (AREA)
Psychology (AREA)
Nutrition Science (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Tropical Medicine & Parasitology (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
Child & Adolescent Psychology (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Communicable Diseases (AREA)
AIDS & HIV (AREA)
Dermatology (AREA)

AT02722625T 2001-05-14 2002-04-26 Tartrate des 5,8,14-triazatetracyclo(10.3.1.02, 11.04,9)-hexadeca-2(11),3,5,7,9-pentaens ATE302607T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US29086101P	2001-05-14	2001-05-14
PCT/IB2002/001437 WO2002092089A1 (en)	2001-05-14	2002-04-26	Tartrate salts of 5,8,14-triazatetracyclo {10.3.1.0?2,11.04,9¿}-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof

Publications (1)

Publication Number	Publication Date
ATE302607T1 true ATE302607T1 (de)	2005-09-15

Family

ID=23117845

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02722625T ATE302607T1 (de)	2001-05-14	2002-04-26	Tartrate des 5,8,14-triazatetracyclo(10.3.1.02, 11.04,9)-hexadeca-2(11),3,5,7,9-pentaens

Country Status (47)

Country	Link
US (2)	US6890927B2 (de)
EP (1)	EP1392307B1 (de)
JP (1)	JP3779682B2 (de)
KR (1)	KR100551184B1 (de)
CN (1)	CN100370987C (de)
AP (1)	AP1473A (de)
AR (1)	AR033635A1 (de)
AT (1)	ATE302607T1 (de)
AU (1)	AU2002253482B2 (de)
BG (1)	BG66408B1 (de)
BR (1)	BR0209605A (de)
CA (1)	CA2447405C (de)
CR (1)	CR7080A (de)
CZ (1)	CZ304763B6 (de)
DE (1)	DE60205742T2 (de)
DK (1)	DK1392307T3 (de)
DO (1)	DOP2002000392A (de)
EA (1)	EA005528B1 (de)
EC (2)	ECSP034850A (de)
EE (1)	EE05441B1 (de)
EG (1)	EG24228A (de)
ES (1)	ES2246396T3 (de)
GE (1)	GEP20053712B (de)
GT (1)	GT200200084A (de)
HR (1)	HRP20030910B1 (de)
HU (1)	HU229867B1 (de)
IL (2)	IL157933A0 (de)
IS (1)	IS2217B (de)
MA (1)	MA27020A1 (de)
ME (1)	ME00466B (de)
MX (1)	MXPA03010364A (de)
MY (1)	MY127807A (de)
NO (1)	NO326148B1 (de)
NZ (1)	NZ528210A (de)
OA (1)	OA12599A (de)
PA (1)	PA8545101A1 (de)
PE (1)	PE20021065A1 (de)
PL (1)	PL214876B1 (de)
PT (1)	PT1392307E (de)
RS (1)	RS50814B (de)
SI (1)	SI1392307T1 (de)
SK (1)	SK287170B6 (de)
TN (1)	TNSN03113A1 (de)
TW (1)	TWI262078B (de)
UA (1)	UA73422C2 (de)
WO (1)	WO2002092089A1 (de)
ZA (1)	ZA200307235B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE386024T1 (de) *	1997-12-31	2008-03-15	Pfizer Prod Inc	Arylkondensierte azapolycyclische derivate
DE60218885T2 (de) *	2001-11-30	2008-01-17	Pfizer Products Inc., Groton	Orale pharmazeutische Arzneiformen bzw. Dosierungsformen von 5,8,14-Triazatetra-cyclo-(10.3.1.0 (2,11).0(4,9)-hexadeca-2(11),3,5,7,9-pentaen mit kontrollierter Freisetzung
WO2004103372A1 (en) *	2003-05-20	2004-12-02	Pfizer Products Inc.	Pharmaceutical compositions of varenicline
US7572914B2 (en) *	2003-12-19	2009-08-11	Takeda Pharmaceutical Company Limited	Kinase inhibitors
WO2005105788A1 (en) *	2004-04-23	2005-11-10	Takeda San Diego, Inc.	Indole derivatives and use thereof as kinase inhibitors
CN1984903A (zh) *	2004-06-30	2007-06-20	伊莱利利公司	1－(吲哚－6－羰基－d－苯基甘氨酰基)－4－(1－甲基哌啶－4－基)哌嗪d－酒石酸盐
WO2006023931A2 (en) *	2004-08-18	2006-03-02	Takeda San Diego, Inc.	Kinase inhibitors
EP1812439B2 (de)	2004-10-15	2017-12-06	Takeda Pharmaceutical Company Limited	Kinaseinhibitoren
EP1802276A1 (de) *	2004-10-15	2007-07-04	Pfizer Products Inc.	Zusammensetzungen und verfahren zur intranasalen, oralen, sublingualen und pulmonalen abgabe von vareniclin
ES2313625T3 (es) *	2005-02-24	2009-03-01	Pfizer Products Incorporated	Preparacion de una quinoxalina sustituida de alta pureza.
US20110086086A1 (en) *	2005-07-26	2011-04-14	Pfizer Inc	Transdermal system for varenicline
US8119655B2 (en) *	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
EP1986994A2 (de) *	2006-02-21	2008-11-05	Teva Pharmaceutical Industries Ltd	Neue kristalline formen von armodafinil und ihre herstellung
EP2223925A1 (de) *	2006-10-09	2010-09-01	Takeda Pharmaceutical Company Limited	Kinase-Inhibitoren
JP2010505962A (ja)	2006-10-09	2010-02-25	武田薬品工業株式会社	キナーゼ阻害剤
MX2009005043A (es) *	2006-11-09	2009-05-25	Pfizer Prod Inc	Polimorfos de intermedios nicotinicos.
US20090062257A1 (en) *	2007-08-29	2009-03-05	Protia, Llc	Deuterium-enriched varenicline
US20090105346A1 (en) *	2007-10-02	2009-04-23	Alexandr Jegorov	Novel crystalline forms of armodafinil and preparation thereof
US20090215787A1 (en) *	2008-02-22	2009-08-27	Mai De Ltd.	Preparations of new polymorphic forms of varenicline tartrate
EP2262780A4 (de) *	2008-03-06	2012-01-25	Reddys Lab Ltd Dr	Amorphes vareniclin-tartrat
WO2009109651A1 (en) *	2008-03-06	2009-09-11	Medichem, S.A.	SALTS OF A PYRAZINO[2,3-h][3]BENZAZEPINE DERIVATIVE
EP2271344A4 (de) *	2008-03-31	2011-04-27	Univ South Florida	Verfahren zur behandlung von krankheitsinduzierter ataxie und nicht-ataxischem ungleichgewicht
EP2268639A2 (de)	2008-05-22	2011-01-05	Teva Pharmaceutical Industries Ltd.	Vareniclin-tosylat, ein zwischenprodukt bei der herstellung von vareniclin-l-tartrat
US20090318460A1 (en) *	2008-05-26	2009-12-24	Glenmark	Amorphous varenicline tartrate and process for the preparation thereof
US20090318695A1 (en) *	2008-06-19	2009-12-24	Vinod Kumar Kansal	Processes for the preparation of varenicline and intermediates thereof
WO2010005643A1 (en) *	2008-07-10	2010-01-14	Teva Pharmaceutical Industries Ltd.	Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
EP2334679A1 (de) *	2008-09-01	2011-06-22	Actavis Group PTC EHF	Verfahren zur herstellung von vareniclin, vareniclinzwischenprodukte und pharmazeutisch unbedenkliche salze davon
US20120093887A1 (en)	2009-06-10	2012-04-19	Actavis Group Ptc Ehf	Amorphous varenicline tartrate co-precipitates
US8178537B2 (en)	2009-06-22	2012-05-15	Teva Pharmaceutical Industries Ltd.	Solid state forms of varenicline salts and processes for preparation thereof
CA2791460A1 (en)	2010-03-09	2011-09-15	Actavis Group Ptc Ehf	Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity
WO2011140431A1 (en)	2010-05-06	2011-11-10	Teva Pharmaceutical Industries Ltd.	Varenicline salts and crystal forms thereof
US9090623B2 (en)	2012-04-13	2015-07-28	Lianyungang Jinkang Hexin Pharmaceutical Co., Ltd.	Compound JK12A and preparation thereof
KR101663550B1 (ko) *	2014-06-11	2016-10-07	조선대학교산학협력단	주석산을 유효성분으로 포함하는 고혈압 예방 또는 치료용 약학조성물 및 건강기능식품
KR101724301B1 (ko)	2016-11-22	2017-04-10	주식회사 한서켐	바레니클린 살리실산염의 i형 결정 및 그 제조방법
WO2018154395A2 (en)	2018-06-11	2018-08-30	Alvogen Malta Operations (Row) Ltd	Controlled release pharmaceutical composition of varenicline
US12569498B2 (en)	2019-11-06	2026-03-10	Children's National Medical Center	Methods and compositions for the prevention and treatment of ischemia reperfusion injury and infection
EP4142734B1 (de)	2020-04-28	2025-08-20	Oyster Point Pharma, Inc.	Lokale verabreichung von nikotinischen acetylcholinrezeptoragonisten zur hemmung von coronavirusinfektionen
CN117715910A (zh) *	2021-08-20	2024-03-15	威智医药股份有限公司	一种亚硝胺杂质、能够减少亚硝胺杂质生成的伐尼克兰药物组合物及其制备与应用
KR20230068877A (ko)	2021-11-11	2023-05-18	주식회사 아울바이오	고용량 바레니클린을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학적 조성물
CN113980020B (zh) *	2021-11-22	2023-05-09	浙江车头制药股份有限公司	一种酒石酸伐尼克兰晶型的制备方法
US20250134904A1 (en)	2021-12-23	2025-05-01	Medichem, S.A.	Solid pharmaceutical formulations of varenicline
US11602537B2 (en)	2022-03-11	2023-03-14	Par Pharmaceutical, Inc.	Varenicline compound and process of manufacture thereof
EP4241775A1 (de)	2022-03-11	2023-09-13	Par Pharmaceutical, Inc.	Tablette mit vareniclin und verfahren zur herstellung davon
EP4540228A1 (de)	2022-06-14	2025-04-23	Amygdala Neurosciences, Inc.	Aldh-2-hemmerverbindungen und verfahren zur verwendung
JP2025520426A (ja)	2022-06-14	2025-07-03	アミグダラニューロサイエンシーズ，インコーポレイテッド	Ａｌｄｈ－２阻害化合物及び使用方法
WO2024095172A1 (en)	2022-11-04	2024-05-10	Pfizer Inc.	Prodrugs of varenicline and compounds containing vulnerable amines
KR102963133B1 (ko)	2023-01-18	2026-05-11	주식회사 아울바이오	고용량 바레니클린을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학 조성물
IT202300003888A1 (it)	2023-03-03	2024-09-03	Dipharma Francis Srl	Processo di preparazione di un farmaco usato per trattare la dipendenza da nicotina
WO2024224270A1 (en)	2023-04-24	2024-10-31	Pfizer Inc.	Varenicline formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3471503A (en)	1967-05-05	1969-10-07	Mcneilab Inc	1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
ATE386024T1 (de) *	1997-12-31	2008-03-15	Pfizer Prod Inc	Arylkondensierte azapolycyclische derivate
IL137937A0 (en) *	1999-08-27	2001-10-31	Pfizer Prod Inc	A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
CZ20011726A3 (cs) *	2000-05-26	2002-02-13	Pfizer Products Inc.	Způsob reakční krystalizace, který umoľňuje řídit velikost částic

2002
- 2002-04-26 HR HR20030910A patent/HRP20030910B1/xx not_active IP Right Cessation
- 2002-04-26 GE GE5341A patent/GEP20053712B/en unknown
- 2002-04-26 UA UA20031110266A patent/UA73422C2/uk unknown
- 2002-04-26 EP EP02722625A patent/EP1392307B1/de not_active Expired - Lifetime
- 2002-04-26 ME MEP-2008-717A patent/ME00466B/me unknown
- 2002-04-26 AU AU2002253482A patent/AU2002253482B2/en not_active Expired
- 2002-04-26 IL IL15793302A patent/IL157933A0/xx unknown
- 2002-04-26 ES ES02722625T patent/ES2246396T3/es not_active Expired - Lifetime
- 2002-04-26 CN CNB028099125A patent/CN100370987C/zh not_active Expired - Lifetime
- 2002-04-26 CA CA002447405A patent/CA2447405C/en not_active Expired - Lifetime
- 2002-04-26 OA OA1200300289A patent/OA12599A/en unknown
- 2002-04-26 PT PT02722625T patent/PT1392307E/pt unknown
- 2002-04-26 BR BR0209605-6A patent/BR0209605A/pt not_active IP Right Cessation
- 2002-04-26 DE DE60205742T patent/DE60205742T2/de not_active Expired - Lifetime
- 2002-04-26 PL PL366551A patent/PL214876B1/pl unknown
- 2002-04-26 SI SI200230189T patent/SI1392307T1/sl unknown
- 2002-04-26 HU HU0304088A patent/HU229867B1/hu unknown
- 2002-04-26 RS YUP-867/03A patent/RS50814B/sr unknown
- 2002-04-26 MX MXPA03010364A patent/MXPA03010364A/es active IP Right Grant
- 2002-04-26 DK DK02722625T patent/DK1392307T3/da active
- 2002-04-26 SK SK1336-2003A patent/SK287170B6/sk not_active IP Right Cessation
- 2002-04-26 KR KR1020037014754A patent/KR100551184B1/ko not_active Expired - Lifetime
- 2002-04-26 EA EA200301121A patent/EA005528B1/ru active Protection Beyond IP Right Term
- 2002-04-26 WO PCT/IB2002/001437 patent/WO2002092089A1/en not_active Ceased
- 2002-04-26 CZ CZ2003-2916A patent/CZ304763B6/cs not_active IP Right Cessation
- 2002-04-26 JP JP2002589006A patent/JP3779682B2/ja not_active Expired - Lifetime
- 2002-04-26 NZ NZ528210A patent/NZ528210A/en not_active IP Right Cessation
- 2002-04-26 EE EEP200300556A patent/EE05441B1/xx unknown
- 2002-04-26 AT AT02722625T patent/ATE302607T1/de active
- 2002-05-06 DO DO2002000392A patent/DOP2002000392A/es unknown
- 2002-05-06 US US10/139,730 patent/US6890927B2/en not_active Expired - Lifetime
- 2002-05-09 AP APAP/P/2002/002523A patent/AP1473A/en active
- 2002-05-10 MY MYPI20021696A patent/MY127807A/en unknown
- 2002-05-10 GT GT200200084A patent/GT200200084A/es unknown
- 2002-05-10 PE PE2002000391A patent/PE20021065A1/es active IP Right Grant
- 2002-05-13 TW TW091109919A patent/TWI262078B/zh not_active IP Right Cessation
- 2002-05-13 AR ARP020101734A patent/AR033635A1/es active IP Right Grant
- 2002-05-13 EG EG20020483A patent/EG24228A/xx active
- 2002-05-14 PA PA20028545101A patent/PA8545101A1/es unknown
2003
- 2003-07-08 TN TNPCT/IB2002/001437A patent/TNSN03113A1/fr unknown
- 2003-09-15 IL IL157933A patent/IL157933A/en active IP Right Grant
- 2003-09-15 IS IS6957A patent/IS2217B/is unknown
- 2003-09-16 ZA ZA200307235A patent/ZA200307235B/en unknown
- 2003-09-22 CR CR7080A patent/CR7080A/es not_active Application Discontinuation
- 2003-11-10 MA MA27389A patent/MA27020A1/fr unknown
- 2003-11-11 BG BG108343A patent/BG66408B1/bg unknown
- 2003-11-13 NO NO20035036A patent/NO326148B1/no not_active IP Right Cessation
- 2003-11-14 EC EC2003004850A patent/ECSP034850A/es unknown
- 2003-11-14 EC EC2003004849A patent/ECSP034849A/es unknown
2005
- 2005-02-28 US US11/069,724 patent/US7265119B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
SI1392307T1 (sl)	2005-12-31
CZ304763B6 (cs)	2014-10-01
RS50814B (sr)	2010-08-31
AP1473A (en)	2005-09-30
ZA200307235B (en)	2004-09-16
AR033635A1 (es)	2003-12-26
TNSN03113A1 (fr)	2005-12-23
NO326148B1 (no)	2008-10-06
MY127807A (en)	2006-12-29
PT1392307E (pt)	2005-11-30
JP2004533446A (ja)	2004-11-04
CN1509174A (zh)	2004-06-30
EE05441B1 (et)	2011-08-15
GT200200084A (es)	2003-09-12
IL157933A (en)	2013-07-31
MA27020A1 (fr)	2004-12-20
TWI262078B (en)	2006-09-21
ME00466B (me)	2011-10-10
DE60205742T2 (de)	2006-05-11
EP1392307A1 (de)	2004-03-03
HUP0304088A2 (hu)	2004-04-28
NZ528210A (en)	2005-04-29
HRP20030910B1 (hr)	2011-11-30
CA2447405A1 (en)	2002-11-21
KR20040010638A (ko)	2004-01-31
YU86703A (sh)	2006-05-25
US20050148591A1 (en)	2005-07-07
GEP20053712B (en)	2005-12-26
IL157933A0 (en)	2004-03-28
PE20021065A1 (es)	2002-11-21
HUP0304088A3 (en)	2011-11-28
CZ20032916A3 (cs)	2004-09-15
CR7080A (es)	2006-08-09
KR100551184B1 (ko)	2006-02-13
OA12599A (en)	2006-06-08
UA73422C2 (en)	2005-07-15
PL214876B1 (pl)	2013-09-30
CN100370987C (zh)	2008-02-27
US7265119B2 (en)	2007-09-04
AU2002253482B2 (en)	2007-09-06
JP3779682B2 (ja)	2006-05-31
ES2246396T3 (es)	2006-02-16
WO2002092089A1 (en)	2002-11-21
BG66408B1 (bg)	2014-01-31
PA8545101A1 (es)	2003-09-05
DOP2002000392A (es)	2002-11-15
EP1392307B1 (de)	2005-08-24
EA200301121A1 (ru)	2004-02-26
US20030166701A1 (en)	2003-09-04
HRP20030910A2 (en)	2004-02-29
EE200300556A (et)	2004-04-15
EA005528B1 (ru)	2005-04-28
BR0209605A (pt)	2004-03-23
HU229867B1 (en)	2014-10-28
NO20035036D0 (no)	2003-11-13
SK13362003A3 (en)	2004-11-03
EG24228A (en)	2008-11-10
DE60205742D1 (de)	2005-09-29
HK1062645A1 (en)	2004-11-19
MXPA03010364A (es)	2004-03-16
IS6957A (is)	2003-09-15
DK1392307T3 (da)	2005-11-07
NO20035036L (no)	2003-11-13
US6890927B2 (en)	2005-05-10
ECSP034849A (es)	2003-12-24
AP2002002523A0 (en)	2002-06-30
SK287170B6 (sk)	2010-02-08
ECSP034850A (es)	2003-12-24
IS2217B (is)	2007-03-15
CA2447405C (en)	2006-10-17
BG108343A (bg)	2004-12-30
PL366551A1 (en)	2005-02-07

Legal Events

Date

Code

Title

Description

2006-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1392307

Country of ref document: EP

Publication	Publication Date	Title
DE60205742D1 (de)	2005-09-29	Tartrate des 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaens
NO20042739L (no)	2004-07-23	Farmasoytiske sammensetninger av 5,6,14-triazatetracyklo(10.3.1.0(2,11).0(4,9))-heksadeca-2(11)3,5,7,9-pentan
DE60214428D1 (de)	2006-10-12	1, 4-dihydro-1, 4-diphenylpyridin-derivate
NO20041567L (no)	2004-05-11	1,8-nafthyridinderivater som antidiabetiske midler
EG23288A (en)	2004-10-31	Water treatment compositions.
ZA200400926B (en)	2005-02-04	Diamine derivatives.
ZA200204020B (en)	2003-11-21	Use of anti-CTLA-4-antibodies.
EE200300557A (et)	2004-04-15	5,8,14-triasatetratsüklo [10,3,1,0 2,11 ,0 4,9]heksadeka-2(11),3,5,7,9-pentaeeni tsitraatsool
ATE323095T1 (de)	2006-04-15	3,7-diazabicycloc3.3.1)-formulierungen als antiarrhythmika
MXPA03007623A (es)	2003-12-04	Derivado de piridopirimidina o naftiridina.
ZA200404807B (en)	2005-08-29	Imidazoquinoline derivatives.
ITGE20020050A0 (it)	2002-06-05	Procedimento per il trattamento di filati mediante agugliatura.
DE60213084D1 (de)	2006-08-24	3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
ITTO20010077V0 (it)	2001-05-29	Gruppo vasca per trattamenti di decapaggio.
ES1048499Y (es)	2001-12-16	Persiana compacta.
ITMI20011344A0 (it)	2001-06-27	Procedimento per la preparazione di 1,3-diossolan-2-oni
DOP2001000275A (es)	2002-05-30	Inhibidores de metaloproteinasa del tipo pirmidin-2,4,6-triona.
IT1318956B1 (it)	2003-09-19	Procedimento per la preparazione di uretani aromatici.
IT1318986B1 (it)	2003-09-19	Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidroisochinolin-3-carbossiammide.
ITMI20001600A0 (it)	2000-07-14	Procedimento per la preparazione di 5-amino-4-alo-3-alchil isossazoli.
ZA200101323B (en)	2002-02-27	Towel.